RB1 and cancer: Our results indicate that SCLC transformed resistant cancers take on many features of classical SCLC, including universal alterations to the RB tumour suppressor, gene expression profiles similar to classical SCLC, which include reduced or absent EGFR expression, and heightened sensitivity to BCL-2 family inhibition.